Select Publications
Journal articles
2020, 'Evaluation of toxicities related to novel therapy in clinical trials for women with gynecologic cancer', Cancer, 126, pp. 2139 - 2145, http://dx.doi.org/10.1002/cncr.32783
,2020, 'Biomarkers of outcome with weekly paclitaxel in platinum-resistant high-grade serous or endometrioid ovarian carcinoma', Gynecologic Oncology, 159, pp. 149 - 149, http://dx.doi.org/10.1016/j.ygyno.2020.05.207
,2020, 'Proactive inter-professional program to manage malignant bowel obstruction (MBO) in women with advanced gynecological cancer: Improving quality of care, education and awareness of malignant bowel obstruction among patients and health care providers', Gynecologic Oncology, 159, pp. 55 - 56, http://dx.doi.org/10.1016/j.ygyno.2020.06.116
,2020, 'Supported self-management as an innovative model of care for advanced gynecologic cancer patients with malignant bowel obstruction: A qualitative study', Gynecologic Oncology, 159, pp. 314 - 315, http://dx.doi.org/10.1016/j.ygyno.2020.05.568
,2019, 'Management of Malignant Pleural Effusions-What Is New', SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 40, pp. 323 - 339, http://dx.doi.org/10.1055/s-0039-1698285
,2019, 'Clinical outcome of sequential chemotherapy after immune checkpoint inhibitors in advanced ovarian cancer.', Journal of Clinical Oncology, 37, pp. 5580 - 5580, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5580
,2019, 'Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.', Journal of Clinical Oncology, 37, pp. 5521 - 5521, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5521
,2019, 'Implementation of malignant bowel obstruction multidisciplinary case conferences (MCCs) to improve clinical decision making in malignant bowel obstruction (MBO) in gynecologic oncology.', Journal of Clinical Oncology, 37, pp. e18322 - e18322, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18322
,2019, 'Optimizing the care of malignant bowel obstruction in patients with advanced gynecologic cancer', Journal of Oncology Practice, 15, pp. e1066 - e1075, http://dx.doi.org/10.1200/JOP.18.00793
,2019, 'To treat or not to treat', JNCI Cancer Spectrum, 3, pp. pkz023, http://dx.doi.org/10.1093/jncics/pkz023
,2018, 'Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial', The Lancet Respiratory Medicine, 6, pp. 671 - 680, http://dx.doi.org/10.1016/S2213-2600(18)30288-1
,2018, 'Prospective assessment of tumor biopsies as part of clinical trials: Patients’ (pts) perspectives.', Journal of Clinical Oncology, 36, pp. 2539 - 2539, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.2539
,2018, 'Toxicity profile of patients with gynecological cancers (Gyne) enrolled in phase I trials.', Journal of Clinical Oncology, 36, pp. 5572 - 5572, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.5572
,2018, 'Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective', Obstetrics and Gynecology International, 2018, pp. 1867238, http://dx.doi.org/10.1155/2018/1867238
,2017, 'Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: The AMPLE randomized clinical trial', JAMA - Journal of the American Medical Association, 318, pp. 1903 - 1912, http://dx.doi.org/10.1001/jama.2017.17426
,2017, 'Novel malignant bowel obstruction (MBO) management program for women with advanced gynecological cancer.', Journal of Clinical Oncology, 35, pp. 158 - 158, http://dx.doi.org/10.1200/jco.2017.35.31_suppl.158
,2017, 'Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer', Familial Cancer, 16, pp. 461 - 469, http://dx.doi.org/10.1007/s10689-017-9977-x
,2017, 'Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers', European Journal of Cancer, 84, pp. 114 - 120, http://dx.doi.org/10.1016/j.ejca.2017.07.004
,2017, 'Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in Australia', Internal Medicine Journal, 47, pp. 888 - 893, http://dx.doi.org/10.1111/imj.13482
,2017, 'Risk-stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program for women with advanced gynecological cancer.', Journal of Clinical Oncology, 35, pp. e18024 - e18024, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e18024
,2017, 'Thoracic ultrasound recognition of competence: A position paper of the Thoracic Society of Australia and New Zealand', Respirology, 22, pp. 405 - 408, http://dx.doi.org/10.1111/resp.12977
,2017, 'Treatment strategies for endometrial cancer: Current practice and perspective', Current Opinion in Obstetrics and Gynecology, 29, pp. 47 - 58, http://dx.doi.org/10.1097/GCO.0000000000000338
,2016, 'Study protocol for a randomised controlled trial of invasive versus conservative management of primary spontaneous pneumothorax', BMJ Open, 6, pp. e011826, http://dx.doi.org/10.1136/BMJOPEN-2016-011826
,2015, 'An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer', Expert Opinion on Investigational Drugs, 24, pp. 1307 - 1320, http://dx.doi.org/10.1517/13543784.2015.1070483
,2015, 'Loss of miR-223 and JNK signaling contribute to elevated stathmin in malignant pleural mesothelioma', Molecular Cancer Research, 13, pp. 1106 - 1118, http://dx.doi.org/10.1158/1541-7786.MCR-14-0442
,2014, 'Protocol of the Australasian Malignant Pleural Effusion (AMPLE) trial: a multicentre randomised study comparing indwelling pleural catheter versus talc pleurodesis', BMJ OPEN, 4, http://dx.doi.org/10.1136/bmjopen-2014-006757
,2013, 'Clinical Outcomes of Indwelling Pleural Catheter-Related Pleural Infections An International Multicenter Study', CHEST, 144, pp. 1597 - 1602, http://dx.doi.org/10.1378/chest.12-3103
,2008, 'School-aged children: A reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom', Journal of Infectious Diseases, 197, pp. 1275 - 1281, http://dx.doi.org/10.1086/586716
,2008, 'Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody', Clinical Infectious Diseases, 46, pp. 186 - 192, http://dx.doi.org/10.1086/524668
,2006, 'Influence of genetic and environmental factors on the immunogenicity of Hib vaccine in Gambian twins', Vaccine, 24, pp. 5335 - 5340, http://dx.doi.org/10.1016/j.vaccine.2006.04.021
,2006, 'Haemophilus influenzae type b reemergence after combination immunization', Emerging Infectious Diseases, 12, pp. 937 - 941, http://dx.doi.org/10.3201/eid1206.051451
,Conference Papers
2024, '713 The impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial (ANZGOG1601)', in Poster and E-Posters, BMJ Publishing Group Ltd, pp. A504.1 - A504, presented at ESGO 2024 Congress Abstracts, http://dx.doi.org/10.1136/ijgc-2024-esgo.988
,2023, 'PO003/#269 Ignite: a phase II signal-seeking trial of adavosertib targeting recurrent high grade serous ovarian cancer with cyclin E1 over-expression with and without gene amplification', in Plenary 01: Oral Abstract Presentations, BMJ Publishing Group Ltd, pp. A2 - A3, presented at IGCS 2023 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2023-igcs.3
,2023, 'PR004/#458 Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in a cohort of patients with advanced ovarian cancer', in Featured Posters: Poster Rounds with the Professors, BMJ Publishing Group Ltd, pp. A32.2 - A33, presented at IGCS 2023 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2023-igcs.47
,2020, '403 Treatment patterns post PARP inhibitor in epithelial ovarian cancer patients: results from an Australian, retrospective, multi-institute cohort study', in Poster, BMJ Publishing Group Ltd, pp. A167.1 - A167, presented at IGCS 2020 Annual Meeting Abstracts, http://dx.doi.org/10.1136/ijgc-2020-igcs.348
,2017, 'Clinical trial of biopsies in oncology: Patient-reported impact (BIOPSY).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.e17034
,2017, 'Immunologic and genomic characterization of high grade serous ovarian cancer (HGSOC) in patients (pts) treated with pembrolizumab (Pembro) in the phase II INSPIRE trial.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5581
,2016, 'Risk of uterine cancer in BRCA1 and BRCA2 mutation carriers.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.1529
,2015, 'LOSS OF MICRORNA-223 AND C-JUN-TERMINAL KINASE (JNK) SIGNALLING CONTRIBUTE TO THE OVER-EXPRESSION OF STATHMIN IN MALIGNANT PLEURAL MESOTHELIOMA', in RESPIROLOGY, WILEY-BLACKWELL, AUSTRALIA, Queensland, pp. 146 - 146, presented at Thoracic Society Australia New Zealand Australian New Zealand Society Respiratory Science Annual Scientific Meeting 2015, AUSTRALIA, Queensland, 27 March 2015 - 01 April 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000351464400379&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'PLEURAL INFECTIONS ASSOCIATED WITH INDWELLING PLEURAL CATHETERS (IPC)', in RESPIROLOGY, WILEY-BLACKWELL, pp. 31 - 31, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000315589700112&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,Conference Abstracts
2024, 'Rates of paclitaxel hypersensitivity reactions using a modified Markman’s infusion protocol as primary prophylaxis', in Supportive Care in Cancer, Vol. 32, http://dx.doi.org/10.1007/s00520-024-08460-z
,2022, 'Dose intensity and outcomes of VDC/IE chemotherapy for adolescent and adult patients with Ewing’s family sarcoma.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 11570 - 11570, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.11570
,2022, 'IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5515 - 5515, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5515
,2022, 'Staging locally advanced cervical cancer with FIGO 2018 versus FIGO 2008: Impact on overall survival and progression-free survival in the OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5531 - 5531, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5531
,2021, 'Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 04 June 2021 - 08 June 2021, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.5584
,2019, 'SOLACE2: A phase II randomised trial of immune priming by olaparib-cyclophosphamide prior to olaparib-durvalumab in asymptomatic, platinum-sensitive recurrent ovarian cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 160 - 161, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400250&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,Preprints
2024, Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer, http://dx.doi.org/10.1101/2024.03.09.24303840
,